The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Impact of previous high-dose melphalan on CAR-T efficacy in patients with myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, comments on the impact of high-dose melphalan on outcomes in patients with multiple myeloma receiving BCMA-directed CAR T-cells, highlighting pre-clinical work that demonstrated that previous exposure to high-dose chemotherapy may lead to T-cell exhaustion and senescence. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
